RAS Mutations in Cancer: Emerging Drug Development Strategies

For four decades, the causal link between RAS mutations in cancer – including the KRAS, HRAS, and NRAS genes – has been well-accepted. But for almost as long, oncology drug development has struggled to develop RAS inhibitors, and many had long...

Read More

For Immediate Release: ProPhase Labs Teams Up With Certis Oncology

Accelerating the Development of Novel Linebacker Compound

Read More

FOR IMMEDIATE RELEASE: SOTERIA Opens Cancer Research Study Leveraging Certis AI and Functional Assays

Dedicated Fund Now Open for Private Contributions

Read More

The Power of Predictive AI Models: Revolutionizing Cancer Research

Powerful computational tools, such as predictive artificial intelligence (AI) models, are reshaping preclinical research, leading to more optimized and streamlined drug discovery and drug development pipelines.1 In drug discovery, AI can be applied...

Read More

Functional Precision Oncology: Filling the Gap Left By Genomics-Based Approaches

Precision oncology (also known as personalized medicine in cancer treatment) is about matching an individual to the optimal therapy for their unique form of cancer. Many people associate personalized medicine with genetic testing. Genomic tumor...

Read More

For Immediate Release: Upcoming Webinar on AI in Cancer Research

OPTIMIZING BIOMARKER DISCOVERY, MODEL SELECTION AND PRECLINICAL DECISION-MAKING Toronto, ON — April 25, 2023 — In this upcoming live webinar hosted by Xtalks, learn about how artificial intelligence (AI) can bring greater speed and precision to...

Read More

FOR IMMEDIATE RELEASE: CERTIS ONCOLOGY SOLUTIONS LAUNCHES PREDICTIVE ANALYTICS PLATFORM

Bioinformatics Solution Combines Artificial Intelligence, Maching Learning and Functional Testing to Elevate Precision Cancer Treatment

Read More

FOR IMMEDIATE RELEASE: Certis Oncology Solutions Announces Three Abstracts Accepted for Presentation at AACR Annual Meeting

Presentations to highlight the value of clinically relevant patient-derived xenograft (PDX) models for translational research and drug development

Read More

How to Overcome the Translation Gap in Cancer Research

Custom Solutions, Better Translation The ultimate goal of drug development in oncology is to identify drug candidates that will successfully advance through the clinical trial pipeline to FDA approval, thus offering individuals with cancer the hope...

Read More

Innovations in Model Development - Upcoming Certis and Xtalks Webinar

In this educational webinar, learn about the latest innovations in preclinical cancer modeling. This talk will cover advancements in patient-derived xenograft (PDX) development, models of spontaneous metastases and other sophisticated approaches to...

Read More